With 23andMe in ‘financial distress,’ California official issues alert to customers
By Jason Green,
The Mercury News
| 03. 24. 2025
With genetic testing company 23andMe facing an increasingly uncertain future, California Attorney General Rob Bonta on Friday reminded customers they have the right to tell the firm to permanently delete their data.
The South San Francisco-based company has publicly reported it is in “financial distress” and stated in recent securities filings that there is substantial doubt about its ability to keep going, the California Attorney General’s Office said in a news release.
The “trove of sensitive consumer data” amassed by 23andMe is subject to deletion under both the Genetic Information Privacy Act and the California Consumer Protection Act, according to the office.
“California has robust privacy laws that allow consumers to take control and request that a company delete their genetic data,” Bonta said in a statement. “Given 23andMe’s reported financial distress, I remind Californians to consider invoking their rights and directing 23andMe to delete their data and destroy any samples of genetic material held by the company.”
Customers can delete their 23andMe account and personal information by taking the following steps:
- Log into your 23andMe account on the...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...